-
Pembrolizumab given to patients with stage two or three bowel cancer and a certain genetic profile (MMR deficient/MSI-High bowel cancer) before surgery instead of chemotherapy led to a significant increase in patients being declared cancer-free, a UK clinical trial found.
Medical Mythbusting Commentary for June 3, 2024 Source:Drug that ‘melts away’ tumours hailed as ‘gamechanger’ for some bowel cancer patients